Vetex Expansion: New $12Mn Injectable Manufacturing Facility Inaugurated in Lurín, Peru

LURÍN, Peru — Veterinary pharmaceutical manufacturer Vetex has officially inaugurated a modern injectable drug production plant in the industrial corridor of Lurín, south of Lima, Peru. Representing a major capital investment aimed at expanding South America’s animal health manufacturing footprint, the new state-of-the-art facility is constructed to increase the company’s regional livestock drug
production capacity and support a targeted 150% surge in regional export volume over the next three years.

The strategic expansion comes in response to rising global demand for protein, expanding herd sizes across South America, and stricter international standards regarding veterinary drug quality, sterile processing, and biosecurity protocols.

Facility Specifications and Technological Capabilities
The Lurín manufacturing complex covers specialized production suites designed around stringent international Good Manufacturing Practices (GMP). Engineered to supply both domestic livestock producers and international trade partners, the facility incorporates automated cleanroom environments, specialized sterile fill-finish suites, and advanced analytical testing laboratories.

Key manufacturing capabilities of the new plant include:

• High-Volume Injectable Lines: Automated sterile liquid filling lines capable of processing multidose glass and high-density polyethylene (HDPE) vials for large-animal therapeutics

• Long-Acting Formulation Suites: Specialized processing equipment tailored for high-viscosity, long- acting (LA) injectable antibiotic suspensions and antiparasitic formulations

• Lyophilization Infrastructure: Industrial freeze-drying units designed for bio-stable injectable vaccines and complex biological molecules

• Quality Control & Traceability: Integrated high-performance liquid chromatography (HPLC) units and digital batch-tracking systems ensuring total supply chain integrity from raw active pharmaceutical ingredients (APIs) to commercial distribution

Strengthening South America’s Livestock Supply Chain
South America remains one of the world’s most critical agricultural engines, holding a major share of global beef and poultry production. However, regional livestock producers face ongoing challenges from endemic parasitic conditions, bovine respiratory disease (BRD), and reproductive loss. The availability of
high-quality, regionally produced veterinary pharmaceuticals is essential to maintain herd health, reduce mortality rates, and secure food safety compliance.

By scaling localized production in Peru, Vetex addresses critical supply chain vulnerabilities that have historically exposed Latin American livestock producers to import delays, currency volatility, and international logistics bottlenecks. The Lurín plant will prioritize the production of essential antiparasitic injectables (such as ivermectin and doramectin formulations), broad-spectrum injectable antibiotics
(oxytetracycline and ceftiofur suspensions), and metabolic rehydration complexes for cattle, swine, and sheep herds.

Furthermore, the 150% export expansion plan targets established agricultural markets across the Andean Community (Ecuador, Colombia, Bolivia) as well as broader Latin American trade corridors in Central America and the Southern Cone. By producing veterinary pharmaceuticals that comply with rigorous international regulatory frameworks, Vetex positions Peru as a rising exporter of high-value
animal health formulations.